OBJECTIVE： To evaluate the results of plasma concentration monitoring of schizophrenia patients after giving Risperidone dispersible tablets， analyze its influential factors and formulate plasma concentration reference value of Risperidone dispersible tablets， and to provide reference of rational drug use in the clinic. METHODS： Totally 204 schizophrenia patients， who used Risperidone dispersible tablets and received plasma concentration monitoring （by trough concentration of risperidone and 9-hydroxyrisperidone） in Xi’an Mental Health Center from Jan.-Dec. 2017， were collected. The plasma concentration of influential factors as gender， age， daily dose and drug combination were analyzed statistically by using SPSS 22.0 software. The proportion of 4th week PANSS reduction rate ＞49％ and ADR were analyzed statistically among patients with different plasma concentrations. RESULTS： Median value of plasma concentration of Risperidone dispersible tablets was 50.55 ng/mL in 204 patients after medication （34.83-73.50 ng/mL）. The gender， drug combination or drug alone had no significant effect on plasma concentration （P＞0.05）. Patient’s age had no significant effect on plasma concentration （P＜0.05）. There is a linear relationship between daily dose of Risperidone dispersible tablets and blood concentration （P＜0.05）. The proportion of 4th week PANSS reduction rate ＞49％ were 13.33％， 34.78％， 53.33％， 47.83％， 38.10％， 38.89％ and 20.00％ for patients with plasma concentration of ＜20， 20～＜30， 30～＜45， 45～＜60， 60～＜90， 90～＜120 and ≥120 ng/mL； the proportion of ADR were 0， 0， 2.22％， 2.17％， 11.90％， 16.67％ and 46.67％， respectively. CONCLUSIONS： The plasma concentration of Risperidone dispersible tablets is affected by age， daily dose and other factors， and there are great individual differences. It is recommended that patients are treated at a plasma concentration of 20-60 ng/mL.